AR042097A1 - Uso de de eritropoyetina para el tratamiento de los trastornos de l a distribucion de hierro en las enfermedades cardiacas - Google Patents
Uso de de eritropoyetina para el tratamiento de los trastornos de l a distribucion de hierro en las enfermedades cardiacasInfo
- Publication number
- AR042097A1 AR042097A1 ARP030104288A ARP030104288A AR042097A1 AR 042097 A1 AR042097 A1 AR 042097A1 AR P030104288 A ARP030104288 A AR P030104288A AR P030104288 A ARP030104288 A AR P030104288A AR 042097 A1 AR042097 A1 AR 042097A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- erythropoyetin
- iron distribution
- cardiac diseases
- distribution disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Uso de eritropoyetina (apoetina alfa, apoetina beta darbe poetina alfa y un conjugado de eritropoyetina entre otras)para el tratamiento de los trastornos de la distribución de hierro en las enfermedades cardíacas. Método de tratamiento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02026342 | 2002-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042097A1 true AR042097A1 (es) | 2005-06-08 |
Family
ID=32337998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104288A AR042097A1 (es) | 2002-11-22 | 2003-11-20 | Uso de de eritropoyetina para el tratamiento de los trastornos de l a distribucion de hierro en las enfermedades cardiacas |
Country Status (16)
Country | Link |
---|---|
US (1) | US7459436B2 (es) |
EP (1) | EP1565206B1 (es) |
JP (1) | JP2006512326A (es) |
KR (1) | KR100839302B1 (es) |
CN (1) | CN100531797C (es) |
AR (1) | AR042097A1 (es) |
AT (1) | ATE426411T1 (es) |
AU (1) | AU2003288081B2 (es) |
BR (1) | BRPI0316438C1 (es) |
CA (1) | CA2505524C (es) |
DE (1) | DE60326874D1 (es) |
ES (1) | ES2321928T3 (es) |
MX (1) | MXPA05005281A (es) |
PL (1) | PL210256B1 (es) |
RU (1) | RU2324494C2 (es) |
WO (1) | WO2004047858A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
JP4674702B2 (ja) | 2003-04-09 | 2011-04-20 | バイオジェネリクス エージー | グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
ES2460671T3 (es) * | 2003-12-19 | 2014-05-14 | F. Hoffmann-La Roche Ag | Uso de eritropoyetina en el tratamiento de alteraciones de la distribución del hierro en enfermedades intestinales inflamatorias crónicas |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
US20070154992A1 (en) | 2005-04-08 | 2007-07-05 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
WO2007026772A1 (ja) * | 2005-08-31 | 2007-03-08 | Kaneka Corporation | ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法 |
US20070072795A1 (en) * | 2005-09-28 | 2007-03-29 | Anton Haselbeck | Treatment of neurodegenerative disorders |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
WO2007092252A2 (en) | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
CN101516388B (zh) | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
ES2406267T3 (es) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Métodos de tratamiento usando G-CSF glicopegilado |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
CN101870735B (zh) * | 2010-06-02 | 2013-06-12 | 北京精益泰翔技术发展有限公司 | 一种新型高糖基化***免疫融合蛋白 |
PE20142405A1 (es) | 2012-04-19 | 2015-01-25 | Opko Biolog Ltd | Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas |
CN112661863A (zh) | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至***羧基端肽来增加多肽的流体动力学体积的方法 |
KR20160030396A (ko) | 2013-07-12 | 2016-03-17 | 옵쏘테크 코포레이션 | 안과적 질환을 치료하거나 예방하기 위한 방법 |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
ES2893616T3 (es) | 2015-06-19 | 2022-02-09 | Opko Biologics Ltd | Factores de coagulación de acción prolongada y métodos para la producción de los mismos |
MX2019000554A (es) | 2016-07-11 | 2019-09-19 | Opko Biologics Ltd | Factor vii de coagulación de acción prolongada y métodos para producir el mismo. |
EP4219537A1 (en) * | 2020-09-22 | 2023-08-02 | Jecho Laboratories, Inc. | Glycosylation-modified erythopoietin and use thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS57183508A (en) * | 1981-05-07 | 1982-11-11 | Nippon Piston Ring Co Ltd | Compound valve seat |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4745099A (en) | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
JP2858752B2 (ja) | 1987-04-10 | 1999-02-17 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
EP0747485B1 (en) | 1989-11-06 | 1998-12-02 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
AU645294B2 (en) | 1989-12-22 | 1994-01-13 | Merck Serono Sa | Endogenous gene expression modification with regulatory element |
GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
US5324650A (en) | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
CA2101918A1 (en) | 1991-03-18 | 1992-09-19 | Samuel Zalipsky | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
IL192290A0 (en) | 1993-08-17 | 2008-12-29 | Kirin Amgen Inc | Erythropoietin analogs |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
ATE200030T1 (de) | 1997-01-29 | 2001-04-15 | Polymasc Pharmaceuticals Plc | Pegylationsverfahren |
EP0977582B1 (de) | 1997-03-18 | 2002-08-14 | Roche Diagnostics GmbH | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
NZ522030A (en) | 2000-05-15 | 2004-11-26 | F | Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition |
US20020065214A1 (en) | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
ES2361824T3 (es) | 2000-12-20 | 2011-06-22 | F. Hoffmann-La Roche Ag | Conjugados de eritropoyetina (epo) con polietilenglicol (peg). |
ATE380346T1 (de) | 2001-09-14 | 2007-12-15 | Hoffmann La Roche | Differentialdiagnose von störungen vom eisenmetabolismus |
-
2003
- 2003-11-12 US US10/706,701 patent/US7459436B2/en not_active Expired - Lifetime
- 2003-11-17 CN CNB2003801038773A patent/CN100531797C/zh not_active Expired - Lifetime
- 2003-11-17 PL PL377590A patent/PL210256B1/pl unknown
- 2003-11-17 AU AU2003288081A patent/AU2003288081B2/en not_active Expired
- 2003-11-17 EP EP03779949A patent/EP1565206B1/en not_active Expired - Lifetime
- 2003-11-17 ES ES03779949T patent/ES2321928T3/es not_active Expired - Lifetime
- 2003-11-17 RU RU2005119649/15A patent/RU2324494C2/ru active
- 2003-11-17 CA CA2505524A patent/CA2505524C/en not_active Expired - Lifetime
- 2003-11-17 KR KR1020057009185A patent/KR100839302B1/ko active IP Right Grant
- 2003-11-17 MX MXPA05005281A patent/MXPA05005281A/es active IP Right Grant
- 2003-11-17 AT AT03779949T patent/ATE426411T1/de active
- 2003-11-17 JP JP2004554368A patent/JP2006512326A/ja active Pending
- 2003-11-17 BR BRPI0316438A patent/BRPI0316438C1/pt active IP Right Grant
- 2003-11-17 WO PCT/EP2003/012822 patent/WO2004047858A1/en active Application Filing
- 2003-11-17 DE DE60326874T patent/DE60326874D1/de not_active Expired - Lifetime
- 2003-11-20 AR ARP030104288A patent/AR042097A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0316438B1 (pt) | 2016-08-02 |
KR20050085091A (ko) | 2005-08-29 |
EP1565206A1 (en) | 2005-08-24 |
BRPI0316438B8 (pt) | 2016-09-27 |
PL377590A1 (pl) | 2006-02-06 |
AU2003288081A1 (en) | 2004-06-18 |
CN100531797C (zh) | 2009-08-26 |
MXPA05005281A (es) | 2005-07-25 |
JP2006512326A (ja) | 2006-04-13 |
ATE426411T1 (de) | 2009-04-15 |
EP1565206B1 (en) | 2009-03-25 |
BR0316438A (pt) | 2005-10-11 |
RU2324494C2 (ru) | 2008-05-20 |
CA2505524C (en) | 2017-02-07 |
RU2005119649A (ru) | 2006-03-20 |
CA2505524A1 (en) | 2004-06-10 |
PL210256B1 (pl) | 2011-12-30 |
CN1713919A (zh) | 2005-12-28 |
WO2004047858A1 (en) | 2004-06-10 |
KR100839302B1 (ko) | 2008-06-17 |
DE60326874D1 (de) | 2009-05-07 |
US20040209802A1 (en) | 2004-10-21 |
AU2003288081B2 (en) | 2007-02-01 |
US7459436B2 (en) | 2008-12-02 |
ES2321928T3 (es) | 2009-06-15 |
BRPI0316438C1 (pt) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042097A1 (es) | Uso de de eritropoyetina para el tratamiento de los trastornos de l a distribucion de hierro en las enfermedades cardiacas | |
ES2191192T3 (es) | Tienopirimidinas. | |
CR8207A (es) | Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo | |
ECSP045069A (es) | Uso de flibanserina en el tratamiento de trastornos sexuales | |
CR7511A (es) | Proceso para la preparacion de 3 quinolina 7 sustituida y 3- quinol-4-ona carbonitrilos | |
ES2101063T3 (es) | Derivados monofluorados de n-propargil-1-amino-indano y su utilizacion como inhibidores de la monoamin-oxidasa. | |
UY27455A1 (es) | Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos. | |
EP1474687A4 (en) | MARK AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE | |
DE122009000036I2 (de) | Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion | |
AR041942A1 (es) | Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria | |
AR053385A1 (es) | Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia | |
EP1636160A4 (en) | NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES | |
DE60324104D1 (en) | Arylsulfonamidobenzylverbindungen | |
ECSP066316A (es) | Uso de la dapsona como neuroprotector en el infarto cerebral | |
BR0315247A (pt) | Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit | |
UY28630A1 (es) | Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol | |
UY26265A1 (es) | Compuestos calciolíticos | |
UY27451A1 (es) | 2,5-diamidoindoles sustituidos y su utilización | |
PT1267915E (pt) | Metodos para tratar doencas com proteina c activada | |
CL2003001692A1 (es) | Uso de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida en la elaboracion de un medicamento para el tratamiento del cancer en un animal de sangre caliente. | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
ECSP034632A (es) | Uso de compuestos del 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria | |
ECSP034636A (es) | Uso de 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria | |
BRPI0509740A (pt) | compostos para tratamento das arritmias cardìacas e métodos de uso | |
ATE532883T1 (de) | Voc-arme fettungsmittel, ihre verwendung in der herstellung und/oder behandlung von leder und häuten, sowie das ensprechende herstellungs- bzw. behandlungsverfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |